Clinical Trial Update: Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GSK134612 meningococcal vaccine with a licensed MenC-CRM197 vaccine in healthy children has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)
• MenC-CRM197 vaccine (CRM197 conjugate meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-10-19